Abingdon Health PLC (LSE:ABDX) - Share price


Stock Report

Abingdon Health PLC ABDX

Last Price
GBX9.25

Day Change
0.00|0.00%

As of 09/08/2022
15:26:21 BST | GBX
Minimum 15 Minutes Delay.

Last Close9.25p
Day Range9.11 - 9.50
Mkt Cap11.26Mil
52-Wk Range7.00 - 84.75
Yield %-
ISINGB00BLF79J41
Volume93,668
P/E-
P/S0.02
P/CF-0.02

Share Price

Total Returns 09/08/2022

 Chg (%)  
More ...
Abingdon Health PLC-7.50 
FTSE 100 TR GBP4.24
 
Financials
201920202021
More ...
Income Statement
Turnover2.285.2411.62
Operating Profit-1.400.22-5.37
Net Profit-1.26-3.37-6.97
Reported EPS-1.31--2.64
Balance Sheet
Current Assets2.247.1822.96
Non Current Assets5.093.7910.27
Total Assets7.3310.9733.23
Current Liabilities0.856.9910.76
Total Liabilities1.248.2211.90
Total Equity6.092.7521.33
Cash Flow
Operating Cash Flow-1.441.89-12.98
Net Change in Cash0.393.520.59
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
21/12/2021PurchaseDr. Christopher William Hand25.00999,599249,900.00
21/12/2021PurchaseMr. Chris Henry Francis Yates25.001,000,000250,000.00

Company Profile

Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, blood cancer, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from products sales. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.

Sector

Diagnostics & Research

Index

FTSE AIM All-Share

Next Event 18/11/2022

Final Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-29.91
Op Mrgn-0.46
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, ChairmanDr. Christopher William Hand
Executive Director, Chief Executive OfficerMr. Chris Henry Francis Yates
Executive Director, Chief Financial OfficerMs. Melanie Ross
Company SecretaryMr. Scott Andrew Page
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.